Uncategorized

Takeda wanted to create something new in the cell therapy world by combining the technology with T cell engagers. A series of acquisitions in 2021 started the process.

Drug pricing criticism often fixates on a price at a single point in time but drug pricing is never static.

Six months after his controversial departure from the top spot at the FDA’s biologics division, Peter Marks has landed at Eli Lilly, joining former colleague Rachael Anatol, who was ousted from the agency not long after Marks.

Six takeaways from the CMS administrator’s appearance at a D.C. think tank Monday — including who’s set to be the next Medicaid director.

CEOs for the systems called the outcome disappointing and did not suggest there would be future plans to merge.

Capacity at the company’s Boston site will increase by 50% as part of a $600 million, 10-year commitment to the U.S.

The deal gives the customer experience firm access to Press Ganey’s extensive healthcare data to bolster artificial intelligence capabilities.

The plaintiffs argue that speech in certain healthcare settings ought to be protected by the First Amendment. Critics say that sets a dangerous precedent, where providers can offer debunked or harmful medical advice with impunity.

MedSec CEO Michelle Jump spoke with MedTech Dive at AdvaMed’s annual meeting about the FDA’s shift from a “carrot” to a “stick” approach in cybersecurity regulation.

At AdvaMed’s The MedTech Conference, executives said they’re incorporating AI in more devices, but figuring out how to use the technology internally is more challenging.